ClinicalTrials.gg
CompletedNCT02282020SOLO3Updated Jul 26, 2022Results posted

Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments

A Phase 3 interventional study of OLAPARIB and Single agent chemotherapy in Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity, sponsored by AstraZeneca. Completed at 94 sites in 13 countries. Open to female participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2022-07-26.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
266
Allocation
Randomized
Ages
18 Years to 130 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 69 studies testing olaparib in Ovarian Neoplasms — 13 open to participants now, 26 under way, 9 of them phase 3. olaparib · Ovarian Neoplasms.

Enrollment
14th of 69
266 · median 97
Started
2015
with 3 others
Phase 3
16 of 69
2 open now
Registered
16th of 69
by date
Lead sponsor
21 of 69
AstraZeneca

Among the 69 studies testing olaparib in Ovarian Neoplasms, this one is the 14th largest by enrollment, is one of 4 that started in 2015, is one of 16 in phase 3, and was the 16th registered.

Ovarian Neoplasms

3,387 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

13 of the 69 studies testing olaparib in Ovarian Neoplasms are open now, in 8 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About olaparib

olaparib: first FDA approval 2014 (LYNPARZA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 602 Ovarian Neoplasms studies recruiting now, 439 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.

This study: 18 Years to 130 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies testing olaparib in Ovarian Neoplasms, or all of them as a file.
02

Study summary

Comparison of olaparib vs. physician's choice of single agent standard of care non-platinum based chemotherapy in patients with germline Breast Cancer susceptibility gene (gBRCA) mutated ovarian cancer who have progressed at least 6 months after the last platinum based chemotherapy. Patient should have received at least 2 prior lines of platinum based chemotherapy. The aim of the study is to assess the efficacy and safety of olaparib tablets.

Read the detailed description

This open label, randomised, controlled, multi-centre study will assess the efficacy and safety of single agent olaparib vs. standard of care, based on physician's choice of single agent chemotherapy ( i.e paclitaxel, or topotecan, or pegylated liposomal doxorubicin, or gemcitabine) in platinum sensitive or partially platinum sensitive relapsed ovarian cancer patients who carry germline deleterious or suspected deleterious BRCA mutation and who have received at least 2 prior lines of platinum based chemotherapy. Patients are eligible to undergo BRCA testing even if they have not yet had recurrence or progression of disease >6 months (>/=183 days) after completion of their last platinum therapy.

03

Conditions studied

  • Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity

Browse trials for

Keywords

  • BRCA, ovarian, platinum, chemotherapy,
04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients must be ≥ 18 years of age
  • Patients with diagnosed high grade serous ovarian cancer (including primary peritoneal and/or fallopian tube cancer) or high grade endometrioid cancer. Patients are eligible to undergo BRCA testing even if they have not yet had recurrence or progression of disease >6 months (>/=183 days) after completion of their last platinum therapy.
  • Documented germline mutation in Breast Cancer susceptibility genes: BRCA1 and/or BRCA2 that is predicted to be deleterious or suspected deleterious (known or predicted to be detrimental/lead to loss of function)
  • At least one lesion that can be accurately assessed at baseline by CT/MRI and is suitable for repeated assessment.
  • Patients must have received at least 2 prior platinum based - Patients must be partially platinum sensitive or platinum sensitive
  • Patients must be suitable to start treatment with single agent chemotherapy based on physician's choice
  • Patients must have normal organ and bone marrow function measured within 28 days of randomisation,
  • (ECOG) performance status 0-2
  • Patients must have a ≥ 16 weeks
  • Formalin fixed, paraffin embedded tumour sample from the primary or recurrent cancer must be available for central testing.

Exclusion criteria

Exclusion Criteria:

  • BRCA 1 and/or BRCA2 mutations that are considered to be non detrimental
  • Exposure to any product within 30 days or 5 half lives (whichever is longer) prior to randomisation
  • Any previous treatment with a Polyadenosine 5'diphosphoribose polymerisation (PARP) inhibitor, including olaparib.
  • Patients who have platinum resistant or disease
  • Patients receiving any systemic chemotherapy within 3 weeks prior to first dose of study treatment
  • Previous single agent exposure to the selected chemotherapy regimen for randomisation. - Prior in the last 5 years, unless curatively treated and recurrence free (few exceptions apply).
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Masking
None (open label)
Enrollment
266 participants (actual)

Study arms

  • Experimental
    1/OLAPARIB

    olaparib 300mg oral tablets; twice daily

    Drug: OLAPARIB

  • Active comparator
    2/CHEMOTHERAPY

    Physician's choice single agent chemotherapy

    Drug: Single agent chemotherapy

Interventions

  • 300 mg olaparib tablets taken orally twice daily. All patients should continue to receive study treatment until objective radiological disease progression as per RECIST 1.1 as assessed by the investigator or the patient experiences unacceptable toxicity or they meet any other discontinuation criteria.

  • DrugSingle agent chemotherapy

    Treatment of relapsed disease with single agent chemotherapy based on physician's choice of weekly paclitaxel, topotecan, pegylated liposomal doxorubicin, or gemcitabine. All patients should continue to receive study treatment until objective radiological disease progression as per RECIST 1.1 as assessed by the investigator or the patient experiences unacceptable toxicity or they meet any other discontinuation criteria

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR)

    To determine the efficacy of olaparib vs. physician's choice single agent chemotherapy by assessment of Objective Response Rate (ORR) using blinded independent central review (BICR) Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 criteria was used by a Blinded Independent Central Review (BICR) to assess participant response to treatment ORR is the number of participants with Complete Response (CR) or Partial Response (PR) in the Measurable Disease Analysis Set (MDAS). Complete response is declared when all lesions have disappeared or all lesions have disappeared and all nodal disease is \< 10 mm each. Partial response is declared when there is a decrease in sum of diameters of target lesions ≥ 30%.

    Time frame: RECIST follow-up assessments performed every 8 weeks (±1 week), up to 48 weeks, then every 12 weeks (±1 week) from randomisation, assessed from date of first patient randomised to data cut off: 10Oct2018 (approx. 3 years 8 months)

Secondary outcomes

  1. Progression Free Survival (PFS)

    To determine the efficacy of single agent olaparib vs. physician's choice single agent chemotherapy by progression free survival (PFS) using BICR assessment according to RECIST 1.1 criteria PFS is defined as the time from randomization until the date of objective radiological disease progression according to RECIST 1.1 or death (by any cause in the absence of disease progression) regardless of whether the participant withdrew from randomized therapy or received another anti-cancer therapy prior to disease progression (i.e., date of RECIST progression/death or censoring - date of randomization +1).

    Time frame: RECIST follow-up assessments performed every 8 weeks (±1 week), up to 48 weeks, then every 12 weeks (±1 week) from randomisation, assessed from date of first patient randomised to data cut off: 10Oct2018 (approx. 3 years 8 months)

  2. Time From Randomisation to Second Progression (PFS2)

    To determine the efficacy of single agent olaparib vs. physician's choice single agent chemotherapy by second progression (PFS2). Time from randomization to PFS2 is defined as the time from the date of randomization to the earliest of the progression events subsequent to first progression or death. The date of second progression was recorded by the investigator and defined according to local standard clinical practice, and could involve objective radiological, clinical, cancer antigen-125 (CA-125) progression or death. CA-125 progression was assessed per Gynecological Cancer Intergroup (GCIG) criteria.

    Time frame: Visits to occur every 12 weeks from the date of first progression, assessed from date of first patient randomised to data cut off: 16Apr2021 (approx. 6 years 2 months)

  3. Overall Survival (OS)

    To determine the efficacy of single agent olaparib vs. physician's choice single agent chemotherapy by overall survival (OS). Overall survival is defined as the time from the date of randomisation until death due to any cause.

    Time frame: Visits to occur every 12 weeks from the date of first progression, assessed from date of first patient randomised to data cut off: 16Apr2021 (approx. 6 years 2 months)

  4. Time To Earliest Progression By RECIST 1.1 Or Cancer Antigen (CA) -125 Or Death

    To determine the efficacy of single agent olaparib vs. physician's choice single agent chemotherapy by time to earliest progression by RECIST 1.1 or CA-125 or death. Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 criteria was used to assess participant response to treatment. CA-125 progression was assessed per Gynecological Cancer Intergroup (GCIG).

    Time frame: RECIST and CA-125 follow-up assessments performed every 8 weeks (±1week), up to 48 weeks, then every 12 weeks (±1week) from randomisation, assessed from date of first patient randomised to data cut off: 10Oct2018 (approx. 3 years 8 months)

  5. Time From Randomization To First Subsequent Therapy Or Death (TFST)

    To determine the efficacy of single agent olaparib vs. physician's choice single agent chemotherapy by time from randomisation to first subsequent therapy or death (TFST) TFST is defined as the time from the date of randomisation to the earlier of first subsequent chemotherapy start date or death. Anti-cancer treatments include chemotherapy and targeted agents.

    Time frame: Anti-cancer treatments initiated post discontinuation of study treatment and investigator's opinion of response and date of progression recorded, assessed from date of first patient randomised to data cut off: 16Apr2021 (approx. 6 years 2 months)

  6. Time From Randomization To Second Subsequent Therapy Or Death (TSST)

    To determine the efficacy of single agent olaparib vs. physician's choice single agent chemotherapy by time from randomisation to second subsequent therapy or death (TSST) TSST was defined as the time from the date of randomisation to the earlier of second subsequent chemotherapy start date or death. Anti-cancer treatments include chemotherapy and targeted agents.

    Time frame: Anti-cancer treatments initiated post discontinuation of study treatment and investigator's opinion of response and date of progression recorded, assessed from date of first patient randomised to data cut off: 16Apr2021 (approx. 6 years 2 months)

  7. Time From Randomization To Study Treatment Discontinuation Or Death (TDT)

    To determine the efficacy of single agent olaparib vs. physician's choice single agent chemotherapy by time to study treatment discontinuation or death (TDT) TDT was defined as the time from randomization to the earlier of the date of study treatment discontinuation or death.

    Time frame: Patients randomised to Olaparib administer their tablets orally at a dose of 300 mg twice daily and continue Olaparib until objective disease progression. Assessed from date of first patient randomised to data cut off: 16Apr2021 (approx. 6 years 2 months)

  8. Duration of Response (DoR)

    To determine the efficacy of single agent olaparib vs. physician's choice single agent chemotherapy by duration of response (DoR) by BICR using RECIST 1.1 criteria for evaluable patients. Duration of response is the time from the first documentation of complete response (CR) or partial response (PR) until the date of progression or death, or the last evaluable RECIST assessment for participants that do not progress or progress after 2 missed assessments. Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 criteria was used to assess participant response to treatment.

    Time frame: RECIST follow-up assessments performed every 8 weeks (±1 week), up to 48 weeks, then every 12 weeks (±1 week) from randomisation, assessed from date of first patient randomised to data cut off: 10Oct2018 (approx. 3 years 8 months)

  9. Time to Response (TTR)

    To determine the efficacy of single agent olaparib vs. physician's choice single agent chemotherapy by time to response (TTR) by BICR using RECIST 1.1 criteria for evaluable patients. TTR was defined as the time from randomization until the date of first documented response by Blinded independent central review (BICR) assessment.

    Time frame: RECIST follow-up assessments performed every 8 weeks (±1 week), up to 48 weeks, then every 12 weeks (±1 week) from randomisation, assessed from date of first patient randomised to data cut off: 10Oct2018 (approx. 3 years 8 months)

  10. Mean Change From Baseline In Trial Outcome Index (TOI) Score

    To compare the efficacy of single agent olaparib versus physician's choice single agent chemotherapy on the Health-related Quality of Life (HRQoL) as measured by the trial outcome index (TOI) of the Functional Assessment of Cancer Therapy - Ovarian (FACT-O) The TOI score was derived from the sum of the scores of the 25 items included in the physical well-being (7 items), functional well-being (7 items), and additional concerns ovarian cancer subscale (11 items) of the FACT-O questionnaire Version 4. TOI score ranges from 0 to 100, a higher score indicates a higher HRQoL. A negative change in score from baseline indicated a worsening in symptoms.

    Time frame: Baseline (Day 1) to Week 48 (±1 week). DCO: 10Oct2018

  11. Number of Participants Who Show an Improvement in TOI Score

    To compare the efficacy of single agent olaparib versus physician's choice single agent chemotherapy on the Health-related Quality of Life (HRQoL) as measured by the trial outcome index (TOI) of the Functional Assessment of Cancer Therapy - Ovarian (FACT-O) The TOI score was derived from the sum of the scores of the 25 items included in the physical well-being (7 items), functional well-being (7 items), and additional concerns ovarian cancer subscale (11 items) of the FACT-O questionnaire Version 4. TOI score ranges from 0 to 100, a higher score indicates a higher health-related quality of life (HRQoL). A change in at least 10 points was considered clinically relevant.

    Time frame: Baseline (Day 1) to Week 48 (±1 week). DCO: 10Oct2018

  12. Objective Response Rate (ORR) in Breast Cancer Susceptibility (BRCA) Gene Population by Blinded Independent Central Review (BICR)

    BRCA gene population includes participants identified as having a deleterious or suspected deleterious variant in either of the BRCA genes using variants identified with current and future BRCA mutation assays (eg, gene sequencing and large rearrangement analysis). The number of participants with complete or partial response per Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 criteria. Partial response is declared when there is a decrease in sum of target disease ≥ 30%. Complete response is declared when all lesions have disappeared or all lesions have disappeared and all nodal disease is \< 10 mm each.

    Time frame: RECIST follow-up assessments performed every 8 weeks (±1 week), up to 48 weeks, then every 12 weeks (±1 week) from randomisation, assessed from date of first patient randomised to data cut off: 10Oct2018 (approx. 3 years 8 months)

  13. Number of Participants Who Experienced Disease Progression or Death in BRCA Gene Population by Blinded Independent Central Review (BICR)

    BRCA gene population includes participants identified as having a deleterious or suspected deleterious variant in either of the BRCA genes using variants identified with current and future BRCA mutation assays (eg, gene sequencing and large rearrangement analysis). Progressive disease was defined as at least 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.

    Time frame: RECIST follow-up assessments performed every 8 weeks (±1 week), up to 48 weeks, then every 12 weeks (±1 week) from randomisation, assessed from date of first patient randomised to data cut off: 10Oct2018 (approx. 3 years 8 months)

  14. Number of Participants Who Experienced Second Progression or Death (PFS2) in BRCA Gene Population

    BRCA gene population includes participants identified as having a deleterious or suspected deleterious variant in either of the BRCA genes using variants identified with current and future BRCA mutation assays (eg, gene sequencing and large rearrangement analysis).

    Time frame: Visits to occur every 12 weeks from the date of first progression, assessed from date of first patient randomised to data cut off: 16Apr2021 (approx. 6 years 2 months)

  15. Overall Survival (OS) in BRCA Gene Population

    BRCA gene population includes participants identified as having a deleterious or suspected deleterious variant in either of the BRCA genes using variants identified with current and future BRCA mutation assays (eg, gene sequencing and large rearrangement analysis). OS in BRCA gene population was measured by the number of participants who died due to any cause.

    Time frame: Visits to occur every 12 weeks from the date of first progression, assessed from date of first patient randomised to data cut off: 16Apr2021 (approx. 6 years 2 months)

  16. Number of Participants Who Discontinued Study Treatment or Died in BRCA Gene Population

    BRCA gene population includes participants identified as having a deleterious or suspected deleterious variant in either of the BRCA genes using variants identified with current and future BRCA mutation assays (eg, gene sequencing and large rearrangement analysis).

    Time frame: Patients randomised to Olaparib administer their tablets orally at a dose of 300 mg twice daily and continue Olaparib until objective disease progression. Assessed from date of first patient randomised to data cut off: 16Apr2021 (approx. 6 years 2 months)

  17. Number of Participants Who Received Subsequent Chemotherapy or Died in BRCA Gene Population

    BRCA gene population includes participants identified as having a deleterious or suspected deleterious variant in either of the BRCA genes using variants identified with current and future BRCA mutation assays (eg, gene sequencing and large rearrangement analysis). Anti-cancer treatments include chemotherapy and targeted agents.

    Time frame: Anti-cancer treatments initiated post discontinuation of study treatment and investigator's opinion of response and date of progression recorded, assessed from date of first patient randomised to data cut off: 16Apr2021 (approx. 6 years 2 months)

  18. Number of Participants Who Received Second Subsequent Chemotherapy or Died in BRCA Gene Population

    BRCA gene population includes participants identified as having a deleterious or suspected deleterious variant in either of the BRCA genes using variants identified with current and future BRCA mutation assays (eg, gene sequencing and large rearrangement analysis). Anti-cancer treatments include chemotherapy and targeted agents.

    Time frame: Anti-cancer treatments initiated post discontinuation of study treatment and investigator's opinion of response and date of progression recorded, assessed from date of first patient randomised to data cut off: 16Apr2021 (approx. 6 years 2 months)

  19. Geometric Mean Plasma Concentration of Olaparib

    Summary of plasma concentrations (ug/mL) of olaparib

    Time frame: Day 1, 1 hour post-dose and Day 29 pre-dose. DCO: 10Oct2018

  20. Number of Participants Who Experience at Least One Adverse Event (AE)

    An AE is the development of an undesirable medical condition or the deterioration of a pre-existing medical condition following or during exposure to a pharmaceutical product, whether or not considered causally related to the product.

    Time frame: Safety Follow-up 30 days after last dose of IP, assessed from the date of first patient randomised to data cut off: 16Apr2021 (approx. 6 years 2 months)

07

Results

Posted Dec 2, 2019

Participant flow

A total of 678 patients were screened (gave informed consent) at 94 centres in 13 countries. Of the 678 patients screened, 266 patients were randomised from 78 sites in 13 countries worldwide. A wash-out period of up to 5 weeks was required for participants who have previously taken potent inhibitors or CYP3A4/5 inducers.

Participant flow — Overall Study
MilestoneOlaparib 300mg BIDSingle Agent Chemotherapy
Started17888
Received treatment17876
Completed190
Not completed15988
Withdrew: Objective disease progression12830
Withdrew: Adverse event1815
Withdrew: Withdrawal by subject710
Withdrew: Miscellaneous519
Withdrew: Severe non-compliance to protocol10
Withdrew: Developed discontinuation criteria02
Withdrew: Withdrew consent prior to dosing012

Outcome measures

PrimaryObjective Response Rate (ORR)

To determine the efficacy of olaparib vs. physician's choice single agent chemotherapy by assessment of Objective Response Rate (ORR) using blinded independent central review (BICR) Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 criteria was used by a Blinded Independent Central Review (BICR) to assess participant response to treatment ORR is the number of participants with Complete Response (CR) or Partial Response (PR) in the Measurable Disease Analysis Set (MDAS). Complete response is declared when all lesions have disappeared or all lesions have disappeared and all nodal disease is \< 10 mm each. Partial response is declared when there is a decrease in sum of diameters of target lesions ≥ 30%.

Time frame:
RECIST follow-up assessments performed every 8 weeks (±1 week), up to 48 weeks, then every 12 weeks (±1 week) from randomisation, assessed from date of first patient randomised to data cut off: 10Oct2018 (approx. 3 years 8 months)
Reported as:
Number · Count of Participants
Objective Response Rate (ORR)
Count of ParticipantsOlaparib 300 mg BIDSingle Agent Chemotherapy
Objective Response Rate (ORR)10937
Statistical analysis
  • Olaparib 300 mg BID vs Single Agent Chemotherapy · Regression, Logistic · p = 0.002 · Odds ratio (or): 2.53 · 95% CI 1.40 to 4.58An odds ratio \>1 favours the olaparib arm
SecondaryProgression Free Survival (PFS)

To determine the efficacy of single agent olaparib vs. physician's choice single agent chemotherapy by progression free survival (PFS) using BICR assessment according to RECIST 1.1 criteria PFS is defined as the time from randomization until the date of objective radiological disease progression according to RECIST 1.1 or death (by any cause in the absence of disease progression) regardless of whether the participant withdrew from randomized therapy or received another anti-cancer therapy prior to disease progression (i.e., date of RECIST progression/death or censoring - date of randomization +1).

Time frame:
RECIST follow-up assessments performed every 8 weeks (±1 week), up to 48 weeks, then every 12 weeks (±1 week) from randomisation, assessed from date of first patient randomised to data cut off: 10Oct2018 (approx. 3 years 8 months)
Reported as:
Median · Months
Progression Free Survival (PFS)
MonthsOlaparib 300 mg BIDSingle Agent Chemotherapy
Progression Free Survival (PFS)13.4 (10.9 to 14.1)9.2 (7.6 to 11.2)
Statistical analysis
  • Olaparib 300 mg BID vs Single Agent Chemotherapy · Log Rank · p = 0.013 (Determined using a log-rank test with a factor for time to disease progression after the end of last platinum based chemotherapy (6-12 months vs \> 12 months).) · Hazard ratio (hr): 0.62 · 95% CI 0.43 to 0.91A hazard ratio \< 1 favours the olaparib arm
SecondaryTime From Randomisation to Second Progression (PFS2)

To determine the efficacy of single agent olaparib vs. physician's choice single agent chemotherapy by second progression (PFS2). Time from randomization to PFS2 is defined as the time from the date of randomization to the earliest of the progression events subsequent to first progression or death. The date of second progression was recorded by the investigator and defined according to local standard clinical practice, and could involve objective radiological, clinical, cancer antigen-125 (CA-125) progression or death. CA-125 progression was assessed per Gynecological Cancer Intergroup (GCIG) criteria.

Time frame:
Visits to occur every 12 weeks from the date of first progression, assessed from date of first patient randomised to data cut off: 16Apr2021 (approx. 6 years 2 months)
Reported as:
Median · Months
Time From Randomisation to Second Progression (PFS2)
MonthsOlaparib 300 mg BIDSingle Agent Chemotherapy
Time From Randomisation to Second Progression (PFS2)23.6 (19.2 to 26.0)19.6 (16.9 to 21.8)
Statistical analysis
  • Olaparib 300 mg BID vs Single Agent Chemotherapy · Log Rank · p = 0.229 (Determined using a log-rank test with a factor for time to disease progression after the end of last platinum based chemotherapy (6-12 months vs \> 12 months).) · Hazard ratio (hr): 0.80 · 95% CI 0.56 to 1.15A hazard ratio \< 1 favours the olaparib arm
SecondaryOverall Survival (OS)

To determine the efficacy of single agent olaparib vs. physician's choice single agent chemotherapy by overall survival (OS). Overall survival is defined as the time from the date of randomisation until death due to any cause.

Time frame:
Visits to occur every 12 weeks from the date of first progression, assessed from date of first patient randomised to data cut off: 16Apr2021 (approx. 6 years 2 months)
Reported as:
Median · Months
Overall Survival (OS)
MonthsOlaparib 300 mg BIDSingle Agent Chemotherapy
Overall Survival (OS)34.9 (30.0 to 39.2)32.9 (23.5 to 43.2)
Statistical analysis
  • Olaparib 300 mg BID vs Single Agent Chemotherapy · Log Rank · p = 0.714 (Determined using a log-rank test with a factor for time to disease progression after the end of last platinum based chemotherapy (6-12 months vs \> 12 months).) · Hazard ratio (hr): 1.07 · 95% CI 0.76 to 1.49A hazard ratio \< 1 favours the olaparib arm
SecondaryTime To Earliest Progression By RECIST 1.1 Or Cancer Antigen (CA) -125 Or Death

To determine the efficacy of single agent olaparib vs. physician's choice single agent chemotherapy by time to earliest progression by RECIST 1.1 or CA-125 or death. Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 criteria was used to assess participant response to treatment. CA-125 progression was assessed per Gynecological Cancer Intergroup (GCIG).

Time frame:
RECIST and CA-125 follow-up assessments performed every 8 weeks (±1week), up to 48 weeks, then every 12 weeks (±1week) from randomisation, assessed from date of first patient randomised to data cut off: 10Oct2018 (approx. 3 years 8 months)
Reported as:
Median · Months
Time To Earliest Progression By RECIST 1.1 Or Cancer Antigen (CA) -125 Or Death
MonthsOlaparib 300 mg BIDSingle Agent Chemotherapy
Time To Earliest Progression By RECIST 1.1 Or Cancer Antigen (CA) -125 Or Death11.1 (9.7 to 13.8)7.9 (6.9 to 9.4)
Statistical analysis
  • Olaparib 300 mg BID vs Single Agent Chemotherapy · Log Rank · p = 0.005 (Determined using a log-rank test with a factor for time to disease progression after the end of last platinum based chemotherapy (6-12 months vs \> 12 months).) · Hazard ratio (hr): 0.59 · 95% CI 0.41 to 0.85A hazard ratio \<1 favours the olaparib arm
SecondaryTime From Randomization To First Subsequent Therapy Or Death (TFST)

To determine the efficacy of single agent olaparib vs. physician's choice single agent chemotherapy by time from randomisation to first subsequent therapy or death (TFST) TFST is defined as the time from the date of randomisation to the earlier of first subsequent chemotherapy start date or death. Anti-cancer treatments include chemotherapy and targeted agents.

Time frame:
Anti-cancer treatments initiated post discontinuation of study treatment and investigator's opinion of response and date of progression recorded, assessed from date of first patient randomised to data cut off: 16Apr2021 (approx. 6 years 2 months)
Reported as:
Median · Months
Time From Randomization To First Subsequent Therapy Or Death (TFST)
MonthsOlaparib 300 mg BIDSingle Agent Chemotherapy
Time From Randomization To First Subsequent Therapy Or Death (TFST)15.4 (13.5 to 17.6)10.9 (9.2 to 14.2)
Statistical analysis
  • Olaparib 300 mg BID vs Single Agent Chemotherapy · Log Rank · p = <0.001 (Model included factors for number of prior chemotherapy regimens received for ovarian cancer (2 or 3 prior lines vs 4 or more lines) and time to disease progression after the end of last platinum based chemotherapy (6-12 months vs \> 12 months).) · Hazard ratio (hr): 0.49 · 95% CI 0.35 to 0.69A hazard ratio \< 1 favours the olaparib arm
SecondaryTime From Randomization To Second Subsequent Therapy Or Death (TSST)

To determine the efficacy of single agent olaparib vs. physician's choice single agent chemotherapy by time from randomisation to second subsequent therapy or death (TSST) TSST was defined as the time from the date of randomisation to the earlier of second subsequent chemotherapy start date or death. Anti-cancer treatments include chemotherapy and targeted agents.

Time frame:
Anti-cancer treatments initiated post discontinuation of study treatment and investigator's opinion of response and date of progression recorded, assessed from date of first patient randomised to data cut off: 16Apr2021 (approx. 6 years 2 months)
Reported as:
Median · Months
Time From Randomization To Second Subsequent Therapy Or Death (TSST)
MonthsOlaparib 300 mg BIDSingle Agent Chemotherapy
Time From Randomization To Second Subsequent Therapy Or Death (TSST)25.2 (21.3 to 27.8)19.9 (18.0 to 24.2)
Statistical analysis
  • Olaparib 300 mg BID vs Single Agent Chemotherapy · Log Rank · p = 0.089 (Model included factors for number of prior chemotherapy regimens received for ovarian cancer (2 or 3 prior lines vs 4 or more lines) and time to disease progression after the end of last platinum based chemotherapy (6-12 months vs \> 12 months).) · Hazard ratio (hr): 0.75 · 95% CI 0.53 to 1.05A hazard ratio \< 1 favours the olaparib arm
SecondaryTime From Randomization To Study Treatment Discontinuation Or Death (TDT)

To determine the efficacy of single agent olaparib vs. physician's choice single agent chemotherapy by time to study treatment discontinuation or death (TDT) TDT was defined as the time from randomization to the earlier of the date of study treatment discontinuation or death.

Time frame:
Patients randomised to Olaparib administer their tablets orally at a dose of 300 mg twice daily and continue Olaparib until objective disease progression. Assessed from date of first patient randomised to data cut off: 16Apr2021 (approx. 6 years 2 months)
Reported as:
Median · Months
Time From Randomization To Study Treatment Discontinuation Or Death (TDT)
MonthsOlaparib 300 mg BIDSingle Agent Chemotherapy
Time From Randomization To Study Treatment Discontinuation Or Death (TDT)13.1 (10.2 to 14.6)5.1 (4.7 to 6.5)
Statistical analysis
  • Olaparib 300 mg BID vs Single Agent Chemotherapy · Log Rank · p = <0.001 (Model included factors for number of prior chemotherapy regimens received for ovarian cancer (2 or 3 prior lines vs 4 or more lines) and time to disease progression after the end of last platinum based chemotherapy (6-12 months vs \> 12 months).) · Hazard ratio (hr): 0.20 · 95% CI 0.14 to 0.29A hazard ratio \< 1 favours the olaparib arm
SecondaryDuration of Response (DoR)

To determine the efficacy of single agent olaparib vs. physician's choice single agent chemotherapy by duration of response (DoR) by BICR using RECIST 1.1 criteria for evaluable patients. Duration of response is the time from the first documentation of complete response (CR) or partial response (PR) until the date of progression or death, or the last evaluable RECIST assessment for participants that do not progress or progress after 2 missed assessments. Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 criteria was used to assess participant response to treatment.

Time frame:
RECIST follow-up assessments performed every 8 weeks (±1 week), up to 48 weeks, then every 12 weeks (±1 week) from randomisation, assessed from date of first patient randomised to data cut off: 10Oct2018 (approx. 3 years 8 months)
Reported as:
Median · Months
Duration of Response (DoR)
MonthsOlaparib 300 mg BIDSingle Agent Chemotherapy
Duration of Response (DoR)9.4 (5.6 to 25.7)10.2 (5.5 to 15.3)
SecondaryTime to Response (TTR)

To determine the efficacy of single agent olaparib vs. physician's choice single agent chemotherapy by time to response (TTR) by BICR using RECIST 1.1 criteria for evaluable patients. TTR was defined as the time from randomization until the date of first documented response by Blinded independent central review (BICR) assessment.

Time frame:
RECIST follow-up assessments performed every 8 weeks (±1 week), up to 48 weeks, then every 12 weeks (±1 week) from randomisation, assessed from date of first patient randomised to data cut off: 10Oct2018 (approx. 3 years 8 months)
Reported as:
Median · Months
Time to Response (TTR)
MonthsOlaparib 300 mg BIDSingle Agent Chemotherapy
Time to Response (TTR)2.0 (1.8 to 3.9)3.5 (1.8 to 3.7)
SecondaryMean Change From Baseline In Trial Outcome Index (TOI) Score

To compare the efficacy of single agent olaparib versus physician's choice single agent chemotherapy on the Health-related Quality of Life (HRQoL) as measured by the trial outcome index (TOI) of the Functional Assessment of Cancer Therapy - Ovarian (FACT-O) The TOI score was derived from the sum of the scores of the 25 items included in the physical well-being (7 items), functional well-being (7 items), and additional concerns ovarian cancer subscale (11 items) of the FACT-O questionnaire Version 4. TOI score ranges from 0 to 100, a higher score indicates a higher HRQoL. A negative change in score from baseline indicated a worsening in symptoms.

Time frame:
Baseline (Day 1) to Week 48 (±1 week). DCO: 10Oct2018
Reported as:
Mean · Scores on a scale
Mean Change From Baseline In Trial Outcome Index (TOI) Score
Scores on a scaleOlaparib 300 mg BIDSelected Chemotherapy
Mean Change From Baseline In Trial Outcome Index (TOI) Score-2.4 ± 11.1-3.6 ± 9.8
Statistical analysis
  • Olaparib 300 mg BID vs Selected Chemotherapy · Mixed Models Analysis · p = 0.108 · Mean difference (final values): 2.5 · 95% CI -0.5 to 5.5Model includes factors for patient, treatment, visit, treatment by visit interaction, baseline TOI score and baseline TOI score by visit interaction.
SecondaryNumber of Participants Who Show an Improvement in TOI Score

To compare the efficacy of single agent olaparib versus physician's choice single agent chemotherapy on the Health-related Quality of Life (HRQoL) as measured by the trial outcome index (TOI) of the Functional Assessment of Cancer Therapy - Ovarian (FACT-O) The TOI score was derived from the sum of the scores of the 25 items included in the physical well-being (7 items), functional well-being (7 items), and additional concerns ovarian cancer subscale (11 items) of the FACT-O questionnaire Version 4. TOI score ranges from 0 to 100, a higher score indicates a higher health-related quality of life (HRQoL). A change in at least 10 points was considered clinically relevant.

Time frame:
Baseline (Day 1) to Week 48 (±1 week). DCO: 10Oct2018
Reported as:
Number · Count of Participants
Number of Participants Who Show an Improvement in TOI Score
Count of ParticipantsOlaparib 300 mg BIDSingle Agent Chemotherapy
Number of Participants Who Show an Improvement in TOI Score255
Statistical analysis
  • Olaparib 300 mg BID vs Single Agent Chemotherapy · Regression, Logistic · p = 0.092 (Estimated from an unadjusted logistic regression model) · Odds ratio (or): 2.24 · 95% CI 0.88 to 6.86An odds ratio \> 1 favours the olaparib arm
SecondaryObjective Response Rate (ORR) in Breast Cancer Susceptibility (BRCA) Gene Population by Blinded Independent Central Review (BICR)

BRCA gene population includes participants identified as having a deleterious or suspected deleterious variant in either of the BRCA genes using variants identified with current and future BRCA mutation assays (eg, gene sequencing and large rearrangement analysis). The number of participants with complete or partial response per Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 criteria. Partial response is declared when there is a decrease in sum of target disease ≥ 30%. Complete response is declared when all lesions have disappeared or all lesions have disappeared and all nodal disease is \< 10 mm each.

Time frame:
RECIST follow-up assessments performed every 8 weeks (±1 week), up to 48 weeks, then every 12 weeks (±1 week) from randomisation, assessed from date of first patient randomised to data cut off: 10Oct2018 (approx. 3 years 8 months)
Reported as:
Number · Count of Participants
Objective Response Rate (ORR) in Breast Cancer Susceptibility (BRCA) Gene Population by Blinded Independent Central Review (BICR)
Count of ParticipantsOlaparib 300 mg BIDSingle Agent Chemotherapy
Objective Response Rate (ORR) in Breast Cancer Susceptibility (BRCA) Gene Population by Blinded Independent Central Review (BICR)10336
Statistical analysis
  • Olaparib 300 mg BID vs Single Agent Chemotherapy · Regression, Logistic · p = 0.004 (Determined using a log-rank test with a factor for time to disease progression after the end of last platinum based chemotherapy (6-12 months vs \> 12 months).) · Odds ratio (or): 2.40 · 95% CI 1.32 to 4.39An odds ratio \> 1 favours the olaparib arm
SecondaryNumber of Participants Who Experienced Disease Progression or Death in BRCA Gene Population by Blinded Independent Central Review (BICR)

BRCA gene population includes participants identified as having a deleterious or suspected deleterious variant in either of the BRCA genes using variants identified with current and future BRCA mutation assays (eg, gene sequencing and large rearrangement analysis). Progressive disease was defined as at least 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.

Time frame:
RECIST follow-up assessments performed every 8 weeks (±1 week), up to 48 weeks, then every 12 weeks (±1 week) from randomisation, assessed from date of first patient randomised to data cut off: 10Oct2018 (approx. 3 years 8 months)
Reported as:
Number · Count of Participants
Number of Participants Who Experienced Disease Progression or Death in BRCA Gene Population by Blinded Independent Central Review (BICR)
Count of ParticipantsOlaparib 300 mg BIDSingle Agent Chemotherapy
Number of Participants Who Experienced Disease Progression or Death in BRCA Gene Population by Blinded Independent Central Review (BICR)10548
Statistical analysis
  • Olaparib 300 mg BID vs Single Agent Chemotherapy · Log Rank · p = 0.014 (Determined using a log-rank test with a factor for time to disease progression after the end of last platinum based chemotherapy (6-12 months vs \> 12 months).) · Hazard ratio (hr): 0.62 · 95% CI 0.42 to 0.91A hazard ratio \< 1 favours the olaparib arm
SecondaryNumber of Participants Who Experienced Second Progression or Death (PFS2) in BRCA Gene Population

BRCA gene population includes participants identified as having a deleterious or suspected deleterious variant in either of the BRCA genes using variants identified with current and future BRCA mutation assays (eg, gene sequencing and large rearrangement analysis).

Time frame:
Visits to occur every 12 weeks from the date of first progression, assessed from date of first patient randomised to data cut off: 16Apr2021 (approx. 6 years 2 months)
Reported as:
Number · Count of Participants
Number of Participants Who Experienced Second Progression or Death (PFS2) in BRCA Gene Population
Count of ParticipantsOlaparib 300 mg BIDSingle Agent Chemotherapy
Number of Participants Who Experienced Second Progression or Death (PFS2) in BRCA Gene Population11048
Statistical analysis
  • Olaparib 300 mg BID vs Single Agent Chemotherapy · Log Rank · p = 0.213 (Determined using a log-rank test with a factor for time to disease progression after the end of last platinum based chemotherapy (6-12 months vs \> 12 months).) · Hazard ratio (hr): 0.80 · 95% CI 0.56 to 1.14A hazard ratio \< 1 favours the olaparib arm
SecondaryOverall Survival (OS) in BRCA Gene Population

BRCA gene population includes participants identified as having a deleterious or suspected deleterious variant in either of the BRCA genes using variants identified with current and future BRCA mutation assays (eg, gene sequencing and large rearrangement analysis). OS in BRCA gene population was measured by the number of participants who died due to any cause.

Time frame:
Visits to occur every 12 weeks from the date of first progression, assessed from date of first patient randomised to data cut off: 16Apr2021 (approx. 6 years 2 months)
Reported as:
Number · Count of Participants
Overall Survival (OS) in BRCA Gene Population
Count of ParticipantsOlaparib 300 mg BIDSingle Agent Chemotherapy
Overall Survival (OS) in BRCA Gene Population11145
Statistical analysis
  • Olaparib 300 mg BID vs Single Agent Chemotherapy · Log Rank · p = 0.699 (Determined using a log-rank test with a factor for time to disease progression after the end of last platinum based chemotherapy (6-12 months vs \> 12 months).) · Hazard ratio (hr): 1.07 · 95% CI 0.76 to 1.51A hazard ratio \< 1 favours the olaparib arm
SecondaryNumber of Participants Who Discontinued Study Treatment or Died in BRCA Gene Population

BRCA gene population includes participants identified as having a deleterious or suspected deleterious variant in either of the BRCA genes using variants identified with current and future BRCA mutation assays (eg, gene sequencing and large rearrangement analysis).

Time frame:
Patients randomised to Olaparib administer their tablets orally at a dose of 300 mg twice daily and continue Olaparib until objective disease progression. Assessed from date of first patient randomised to data cut off: 16Apr2021 (approx. 6 years 2 months)
Reported as:
Number · Count of Participants
Number of Participants Who Discontinued Study Treatment or Died in BRCA Gene Population
Count of ParticipantsOlaparib 300 mg BIDSingle Agent Chemotherapy
Number of Participants Who Discontinued Study Treatment or Died in BRCA Gene Population15176
Statistical analysis
  • Olaparib 300 mg BID vs Single Agent Chemotherapy · Log Rank · p = <0.001 (Model included factors for number of prior chemotherapy regimens received for ovarian cancer (2 or 3 prior lines vs 4 or more lines) and time to disease progression after the end of last platinum based chemotherapy (6-12 months vs \> 12 months).) · Hazard ratio (hr): 0.18 · 95% CI 0.12 to 0.27A hazard ratio \< 1 favours the olaparib arm
SecondaryNumber of Participants Who Received Subsequent Chemotherapy or Died in BRCA Gene Population

BRCA gene population includes participants identified as having a deleterious or suspected deleterious variant in either of the BRCA genes using variants identified with current and future BRCA mutation assays (eg, gene sequencing and large rearrangement analysis). Anti-cancer treatments include chemotherapy and targeted agents.

Time frame:
Anti-cancer treatments initiated post discontinuation of study treatment and investigator's opinion of response and date of progression recorded, assessed from date of first patient randomised to data cut off: 16Apr2021 (approx. 6 years 2 months)
Reported as:
Number · Count of Participants
Number of Participants Who Received Subsequent Chemotherapy or Died in BRCA Gene Population
Count of ParticipantsOlaparib 300 mg BIDSelected Chemotherapy
Number of Participants Who Received Subsequent Chemotherapy or Died in BRCA Gene Population13866
Statistical analysis
  • Olaparib 300 mg BID vs Selected Chemotherapy · Log Rank · p = <0.001 (Model included factors for number of prior chemotherapy regimens received for ovarian cancer (2 or 3 prior lines vs 4 or more lines) and time to disease progression after the end of last platinum based chemotherapy (6-12 months vs \> 12 months).) · Hazard ratio (hr): 0.46 · 95% CI 0.33 to 0.66A hazard ratio \< 1 favours the olaparib arm
SecondaryNumber of Participants Who Received Second Subsequent Chemotherapy or Died in BRCA Gene Population

BRCA gene population includes participants identified as having a deleterious or suspected deleterious variant in either of the BRCA genes using variants identified with current and future BRCA mutation assays (eg, gene sequencing and large rearrangement analysis). Anti-cancer treatments include chemotherapy and targeted agents.

Time frame:
Anti-cancer treatments initiated post discontinuation of study treatment and investigator's opinion of response and date of progression recorded, assessed from date of first patient randomised to data cut off: 16Apr2021 (approx. 6 years 2 months)
Reported as:
Number · Count of Participants
Number of Participants Who Received Second Subsequent Chemotherapy or Died in BRCA Gene Population
Count of ParticipantsOlaparib 300 mg BIDSingle Agent Chemotherapy
Number of Participants Who Received Second Subsequent Chemotherapy or Died in BRCA Gene Population12756
Statistical analysis
  • Olaparib 300 mg BID vs Single Agent Chemotherapy · Log Rank · p = 0.055 (Model included factors for number of prior chemotherapy regimens received for ovarian cancer (2 or 3 prior lines vs 4 or more lines) and time to disease progression after the end of last platinum based chemotherapy (6-12 months vs \> 12 months).) · Hazard ratio (hr): 0.72 · 95% CI 0.51 to 1.01A hazard ratio \< 1 favours the olaparib arm
SecondaryGeometric Mean Plasma Concentration of Olaparib

Summary of plasma concentrations (ug/mL) of olaparib

Time frame:
Day 1, 1 hour post-dose and Day 29 pre-dose. DCO: 10Oct2018
Reported as:
Geometric mean · μg/mL
Geometric Mean Plasma Concentration of Olaparib
μg/mLOlaparib 300 mg BID
Day 1, 1 hour post-dose4.76 ± 112.93
Day 29, pre-dose1.78 ± 100.54
SecondaryNumber of Participants Who Experience at Least One Adverse Event (AE)

An AE is the development of an undesirable medical condition or the deterioration of a pre-existing medical condition following or during exposure to a pharmaceutical product, whether or not considered causally related to the product.

Time frame:
Safety Follow-up 30 days after last dose of IP, assessed from the date of first patient randomised to data cut off: 16Apr2021 (approx. 6 years 2 months)
Reported as:
Number · Count of Participants
Number of Participants Who Experience at Least One Adverse Event (AE)
Count of ParticipantsOlaparib 300 mg BIDSingle Agent Chemotherapy
Number of Participants Who Experience at Least One Adverse Event (AE)17573

Adverse events

Collected over Includes all AEs that had a start date or a worsening (increase in CTCAE grade) after the start of treatment up until the end of the 30 day follow-up period. The 30 day follow-up period will be defined as 30 days following discontinuation of olaparib/chemotherapy treatment. Assessed from randomisation to data cut off. DCO: 16Apr2021. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Olaparib 300 mg bd116/178 (65.2%)46/178 (25.8%)173/178 (97.2%)
Single Agent Chemotherapy46/88 (52.3%)14/76 (18.4%)73/76 (96.1%)
Most frequent serious events
Showing 10 of 55
Most frequent serious events
EventOlaparib 300 mg bdSingle Agent Chemotherapy
VomitingGastrointestinal disorders3/1783/76
AnaemiaBlood and lymphatic system disorders6/1780/76
PyrexiaGeneral disorders2/1782/76
Pleural effusionRespiratory, thoracic and mediastinal disorders3/1782/76
NauseaGastrointestinal disorders2/1782/76
Deep vein thrombosisVascular disorders3/1780/76
Abdominal pain upperGastrointestinal disorders0/1781/76
Intestinal obstructionGastrointestinal disorders2/1781/76
Mesenteric vein thrombosisGastrointestinal disorders0/1781/76
MalaiseGeneral disorders0/1781/76
Most frequent other events
Showing 10 of 61
Most frequent other events
EventOlaparib 300 mg bdSingle Agent Chemotherapy
NauseaGastrointestinal disorders115/17824/76
AnaemiaBlood and lymphatic system disorders87/17819/76
VomitingGastrointestinal disorders66/17814/76
FatigueGeneral disorders66/17820/76
Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders1/17827/76
DiarrhoeaGastrointestinal disorders52/17813/76
NeutropeniaBlood and lymphatic system disorders29/17822/76
Abdominal painGastrointestinal disorders41/17811/76
ConstipationGastrointestinal disorders24/17817/76
AstheniaGeneral disorders35/17812/76

Baseline characteristics

Baseline characteristics are displayed for all participants who started the study. This includes the 12 participants who did not receive treatment in the 'Single Agent Chemotherapy' arm.

Age, Continuous
Age, Continuous(Years)Olaparib 300mg BIDSingle Agent ChemotherapyTotal
Mean58.5 ± 9.360.4 ± 9.959.2 ± 9.5
Sex: Female, Male
Sex: Female, Male(Participants)Olaparib 300mg BIDSingle Agent ChemotherapyTotal
Female17888266
Male000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Olaparib 300mg BIDSingle Agent ChemotherapyTotal
Hispanic or Latino311647
Not Hispanic or Latino14672218
Unknown or Not Reported101
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Olaparib 300mg BIDSingle Agent ChemotherapyTotal
White14875223
Black Or African American112
Asian241034
American Indian Or Alaska Native426
Other101
08

Study locations

94 sites
  • Research Site
    Birmingham, Alabama 35233, United States
  • Research Site
    Mobile, Alabama 36604, United States
  • Research Site
    Sacramento, California 95817, United States
  • Research Site
    San Francisco, California 94118, United States
  • Research Site
    Aurora, Colorado 80045, United States
  • Research Site
    Littleton, Colorado 80120, United States
  • Research Site
    Hartford, Connecticut 06106, United States
  • Research Site
    Fort Gordon, Georgia 30905, United States
  • Research Site
    Covington, Louisiana 70433, United States
  • Research Site
    Towson, Maryland 21204, United States
  • Research Site
    Detroit, Michigan 48201, United States
  • Research Site
    Albany, New York 12208, United States
  • Research Site
    Mineola, New York 11501, United States
  • Research Site
    Chapel Hill, North Carolina 27599, United States
  • Research Site
    Columbus, Ohio 43210, United States
  • Research Site
    Springfield, Oregon 97477, United States
  • Research Site
    Abington, Pennsylvania 19001, United States
  • Research Site
    Knoxville, Tennessee 37920, United States
  • Research Site
    Nashville, Tennessee 37232, United States
  • Research Site
    Bedford, Texas 76022, United States
  • Research Site
    Houston, Texas 77030, United States
  • Research Site
    Milwaukee, Wisconsin 53226, United States
  • Research Site
    Berazategui, B1884BBF, Argentina
  • Research Site
    Caba, C1280AEB, Argentina
  • Research Site
    Ciudad de Buenos Aires, C1180AAX, Argentina
  • Research Site
    Cordoba, 5000, Argentina
  • Research Site
    La Plata, B1897GPD, Argentina
  • Research Site
    San Miguel de Tucumán, T4000IAK, Argentina
  • Research Site
    Gent, 9000, Belgium
  • Research Site
    Leuven, 3000, Belgium
  • Research Site
    Ijui, 98700-000, Brazil
  • Research Site
    Passo Fundo, 99010 260, Brazil
  • Research Site
    Porto Alegre, 90035-003, Brazil
  • Research Site
    Porto Alegre, 90610-000, Brazil
  • Research Site
    Rio de Janeiro, 22793-080, Brazil
  • Research Site
    Sao Paulo, 01246-000, Brazil
  • Research Site
    Sao Paulo, 01317-000, Brazil
  • Research Site
    São José do Rio Preto, 15090-000, Brazil
  • Research Site
    Toronto, Ontario M4N 3M5, Canada
  • Research Site
    Toronto, Ontario M5G 1X6, Canada
  • Research Site
    Montreal, Quebec H2L 4M1, Canada
  • Research Site
    Hradec Kralove, 500 05, Czechia
  • Research Site
    Ostrava-Poruba, 708 52, Czechia
  • Research Site
    Praha 2, 128 08, Czechia
  • Research Site
    Zlin, 762 75, Czechia
  • Research Site
    Budapest, 1088, Hungary
  • Research Site
    Budapest, 1115, Hungary
  • Research Site
    Budapest, 1122, Hungary
  • Research Site
    Debrecen, 4032, Hungary
  • Research Site
    Győr, 9024, Hungary
  • Research Site
    Miskolc, 3526, Hungary
  • Research Site
    Afula, 18101, Israel
  • Research Site
    Haifa, 31096, Israel
  • Research Site
    Holon, 58100, Israel
  • Research Site
    Jerusalem, 9103102, Israel
  • Research Site
    Jerusalem, 91120, Israel
  • Research Site
    Petah Tikva, 4941492, Israel
  • Research Site
    Ramat Gan, 52621, Israel
  • Research Site
    Rehovot, 7661041, Israel
  • Research Site
    Tel Hashomer, 52621, Israel
  • Research Site
    Tel-Aviv, 6423906, Israel
  • Research Site
    Zerifin, 70300, Israel
  • Research Site
    Meldola, 47014, Italy
  • Research Site
    Messina, 98158, Italy
  • Research Site
    Milano, 20132, Italy
  • Research Site
    Milano, 20133, Italy
  • Research Site
    Milano, 20141, Italy
  • Research Site
    Napoli, 80131, Italy
  • Research Site
    Roma, 00144, Italy
  • Research Site
    Roma, 00168, Italy
  • Research Site
    Goyang-si, 10408, Korea, Republic of
  • Research Site
    Seoul, 03080, Korea, Republic of
  • Research Site
    Seoul, 06273, Korea, Republic of
  • Research Site
    Seoul, 06351, Korea, Republic of
  • Research Site
    Seoul, 138-736, Korea, Republic of
  • Research Site
    Seoul, 139-706, Korea, Republic of
  • Research Site
    Mexico, 07760, Mexico
  • Research Site
    Mexico, 6760, Mexico
  • Research Site
    Oaxaca, 68000, Mexico
  • Research Site
    Gdańsk, 80-219, Poland
  • Research Site
    Grzepnica, 72-003, Poland
  • Research Site
    Lublin, 20-090, Poland
  • Research Site
    Olsztyn, 10-561, Poland
  • Research Site
    Poznan, 60-569, Poland
  • Research Site
    Warszawa, 02-781, Poland
  • Research Site
    Łódź, 93-513, Poland
  • Research Site
    Barcelona, 08035, Spain
  • Research Site
    Barcelona, 08036, Spain
  • Research Site
    Barcelona, 08907, Spain
  • Research Site
    Córdoba, 14004, Spain
  • Research Site
    Gerona, 17007, Spain
  • Research Site
    Granada, 18014, Spain
  • Research Site
    Madrid, 28040, Spain
  • Research Site
    Madrid, 28050, Spain
09

References and documents

Publications

  • Paulino E, Melo AC. SOLO 3 Trial: How Do the Results Fit in With Current Evidence? J Clin Oncol. 2020 Aug 10;38(23):2697-2698. doi: 10.1200/JCO.20.00576. Epub 2020 Jun 12. No abstract available. PubMed 32530768 ↗
  • Penson RT, Lowe ES. Reply to E. Paulino et al. J Clin Oncol. 2020 Aug 10;38(23):2698. doi: 10.1200/JCO.20.01235. Epub 2020 Jun 12. No abstract available. PubMed 32530766 ↗
  • Penson RT, Valencia RV, Cibula D, Colombo N, Leath CA 3rd, Bidzinski M, Kim JW, Nam JH, Madry R, Hernandez C, Mora PAR, Ryu SY, Milenkova T, Lowe ES, Barker L, Scambia G. Olaparib Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a Germline BRCA1/2 Mutation (SOLO3): A Randomized Phase III Trial. J Clin Oncol. 2020 Apr 10;38(11):1164-1174. doi: 10.1200/JCO.19.02745. Epub 2020 Feb 19. PubMed 32073956 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2015 to primary completion in Oct 2018, 44 months.

Results were first posted in Dec 2019, 1 year 1 month after primary completion.

Of 73 industry-sponsored phase 3 interventional studies under Ovarian Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 72. This study's 44 months is close to that.

Counting every sponsor, half of 125 studies reached it within 59 months; a quarter within 37 and three quarters within 89.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 20, 2014
First posted
Nov 4, 2014
StartActual
Feb 6, 2015
Primary completionActual
Oct 10, 2018
CompletionActual
Jul 19, 2022
Results first posted
Dec 2, 2019
Last update
Jul 26, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 26, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02282020
Lead sponsor
AstraZeneca
Collaborators
Myriad Genetic Laboratories, Inc., Merck Sharp & Dohme LLC
Responsible party
Sponsor
First posted
Nov 4, 2014
Start date
Feb 6, 2015
Primary completion
Oct 10, 2018
Completion
Jul 19, 2022
Results posted
Dec 2, 2019
Last update
Jul 26, 2022

Study contacts

Richard T Penson, Associate Prof. of Medicine
principal investigator · Harvard Medical School (HMS and HSDM)

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Olaparib

Start the discussion